
CC-115
CAS No. 1228013-15-7
CC-115( —— )
Catalog No. M10883 CAS No. 1228013-15-7
A novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 43 | In Stock |
![]() ![]() |
5MG | 69 | In Stock |
![]() ![]() |
10MG | 113 | In Stock |
![]() ![]() |
25MG | 214 | In Stock |
![]() ![]() |
50MG | 383 | In Stock |
![]() ![]() |
100MG | 565 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCC-115
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively.
-
DescriptionA novel dual inhibitor of mTOR and DNA-PK with IC50 of 21 nM and 13 nM, respectively; blocks both mTORC1(pS6) and mTORC2(pAktS473) signaling in PC-3 cancer cells, in vitro and in vivo; exhibits dose-dependent efficacy in tumor xenograft models.Blood Cancer Phase 1 Clinical(In Vitro):CC-115 inhibits PC-3 cells proliferation with an IC50 of 138 nM. In a kinase selectivity assessment against a panel of 250 protein kinases at 3 μM, only one kinase other than mTOR kinase is identified with more than 50% inhibition (cFMS 57%, IC50=2.0 μM). Of the PI3K related kinases (PIKKs) tested, CC-115 proves to be equipotent against DNA PK (IC50=15 nM) and demonstrates 40 to >1000 fold selectivity against the remaining PIKKs tested; PI3K-alpha (IC50=0.85 μM), ATR (50% inhibition at 30 μM) and ATM (IC50>30 μM). The IC50 values for CC-115 are >10 μM against a panel of CYP enzymes and >33 μM for the hERG (human ether-a-go-go-related gene) ion channel. When screened in a single point assay at 10 μM against a Cerep receptor and enzyme panel only one target is inhibited >50% (PDE3, IC50=0.63 μM).(In Vivo):CC-115 shows good in vivo PK profiles across multiple species with 53%, 76% and ~100% oral bioavailability in mouse, rat and dog, respectively. CC-115 is tested at lower doses of 0.25, 0.5 and 1 mg/kg bid or 1 mg/kg qd, with observed corresponding tumor volume reductions of 46%, 57%, 66% and 57% respectively. CC-115 sustains inhibition though 24 hours. At the 1 mg/kg dose CC-115 shows significant inhibition at 1 and 3 hours, CC-115 demonstrating inhibition through 10 hours. CC-115 is evaluated using both once (qd) and twice (bid) daily dosing schedules.
-
In VitroCC-115 inhibits PC-3 cells proliferation with an IC50 of 138 nM. In a kinase selectivity assessment against a panel of 250 protein kinases at 3 μM, only one kinase other than mTOR kinase is identified with more than 50% inhibition (cFMS 57%, IC50=2.0 μM). Of the PI3K related kinases (PIKKs) tested, CC-115 proves to be equipotent against DNA PK (IC50=15 nM) and demonstrates 40 to >1000 fold selectivity against the remaining PIKKs tested; PI3K-alpha (IC50=0.85 μM), ATR (50% inhibition at 30 μM) and ATM (IC50>30 μM). The IC50 values for CC-115 are >10 μM against a panel of CYP enzymes and >33 μM for the hERG (human ether-a-go-go-related gene) ion channel. When screened in a single point assay at 10 μM against a Cerep receptor and enzyme panel only one target is inhibited >50% (PDE3, IC50=0.63 μM).
-
In VivoCC-115 shows good in vivo PK profiles across multiple species with 53%, 76% and ~100% oral bioavailability in mouse, rat and dog, respectively. CC-115 is tested at lower doses of 0.25, 0.5 and 1 mg/kg bid or 1 mg/kg qd, with observed corresponding tumor volume reductions of 46%, 57%, 66% and 57% respectively. CC-115 sustains inhibition though 24 hours. At the 1 mg/kg dose CC-115 shows significant inhibition at 1 and 3 hours, CC-115 demonstrating inhibition through 10 hours. CC-115 is evaluated using both once (qd) and twice (bid) daily dosing schedules.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorDNA-PK|mTOR|PI3Kα
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1228013-15-7
-
Formula Weight336.3512
-
Molecular FormulaC16H16N8O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 32 mg/mL
-
SMILESCCN1C(=O)CNC2=NC=C(N=C21)C3=C(N=C(C=C3)C4=NC=NN4)C
-
Chemical NamePyrazino[2,3-b]pyrazin-2(1H)-one, 1-ethyl-3,4-dihydro-7-[2-methyl-6-(1H-1,2,4-triazol-5-yl)-3-pyridinyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mortensen DS, et al. J Med Chem. 2015 Jul 23;58(14):5599-608.
2. Thijssen R, et al. Blood. 2016 Jul 28;128(4):574-83.
molnova catalog



related products
-
MTI-31
MTI-31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR).
-
PP 242
A potent, specific active-site inhibitor of mTOR with IC50 of 30 and 58 nM for mTORC1 and mTORC2, respectively.
-
ElteN378
ElteN378 is a highly potent synthetic inhibitor of FKBP12 with Ki of 0.5 nM, a low atomic weight ligand with affinity comparable to that of the macrolide Rapamycin.